TP53 loss and TET2 deficiency cooperate to drive lineage-plastic leukemogenesis by transforming progenitors and establishing immune suppressive environment
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA901155 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| Other | ||||
| SRR22270200_1.fastq.gz | Fastqsanger.gz | |||
| SRR22270200_2.fastq.gz | Fastqsanger.gz | |||
| SRR22270201_1.fastq.gz | Fastqsanger.gz | |||
| SRR22270201_2.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 121 |
Similar Datasets
Project description:Loss-of-function mutations of TET2 and TP53 genes are frequently co-observed in AML patients receiving intensive chemotherapy and represent independent predictors for inferior survival in patients after stem cell transplantation. Here we show that TET2 biallelic loss or haploinsufficiency is observed in >10% AML patients with TP53 mutations and associated with poor outcome. In mice, double deletions of TET2 and P53 leads to development of T-ALL, B-ALL or AML and stimulation of pre-leukemic mice via TLR2-TRAF6-A20 axis skews leukemia development toward AML. scRNA-seq of murine blasts reveals that B cell leukemia differentiation is accompanied by transcriptional changes of ll7r and Myb while AML commitment is associated with dynamic elevation of Klf4 and Flt3. Notably, mice with AML exhibit T cell exhaustion, NK dysfunction, and MDSC-like properties which are similarly observed in AML patients with TP53/TET2 co-mutations. Lastly, we demonstrated that silencing of MEK/ERK, JAK/STAT or TLR-A20 signaling pathways, that are overexpressed in TP53/TET2-mutant AML, restores normal differentiation in vitro and in vivo. Collectively, these findings provide evidence that TP53 deficiency and TET2 loss cooperate to transform hematopoietic progenitors and play a role in AML development and identify novel targets to deliver therapy for this high-risk AML group.
2023-11-13 | GSE217867 | GEO
Project description:Proteomics of transforming vs. non-transforming lichen planus.
2022-08-15 | MSV000090139 | MassIVE
Project description:This SuperSeries is composed of the following subset Series: GSE16432: MSI2 regulates hematopoiesis and accelerates leukemogenesis GSE22773: Musashi 2 regulates normal hematopoiesis and accelerates leukemogenesis (LK and MS12-inducible) GSE22774: Musashi 2 regulates normal hematopoiesis and accelerates leukemogenesis (LSK and LK) GSE22775: Musashi 2 regulates normal hematopoiesis and accelerates leukemogenesis (Leukemia cell lines) Refer to individual Series
2010-07-21 | E-GEOD-22778 | biostudies-arrayexpress
Project description:Aneuploidy and structural aberrations affecting chromosome 21 (Hsa21) are the most frequent in cytogentic events in acute myeloid leukemia. However, it remains unclear why leukemic blasts select for amplifications of Hsa21 or parts of it and why children with Down syndrome (i.e. trisomy 21) are at a high risk of developing leukemia. Here, we propose that disequilibrium of the RUNX1 isoforms and resultant RUNX1A dominance are key to trisomy 21-associated leukemogenesis. Using a Hsa21-focussed CRISPR-Cas9 screen, we uncovered a strong and specific RUNX1 dependency in myeloid leukemia associated with Down syndrome (ML-DS). High levels of RUNX1A – as seen in ML-DS – synergized with the pathognomonic Gata1s mutation in ML-DS pathogenesis, an effect that was reversed upon restoration of the normal RUNX1A:RUNX1C equilibrium. Mechanistically, RUNX1A displaces RUNX1C from its endogenous binding sites and recruits the MYC cofactor MAX to induce oncogenic programs and perturb normal differentiation. This presents a therapeutic vulnerability that can be exploited by interfering with MYC:MAX dimerization. Our study highlights the importance of alternative splicing in leukemogenesis, and paves the way for developing specific and targeted therapies for ML-DS as well as for other leukemias with Hsa21 aneuploidy or RUNX1 isoform disequilibrium.
2023-05-10 | PXD030616 | Pride
Project description:This SuperSeries is composed of the following subset Series: GSE24646: h3k36me3-Establishing a reference epigenome in arabidopsis seedlings GSE24647: h3k9me2-Establishing a reference epigenome in arabidopsis seedlings GSE24648: h3k4me2-Establishing a reference epigenome in arabidopsis seedlings GSE24649: h3k4me3-Establishing a reference epigenome in arabidopsis seedlings GSE24650: h3k9me3-Establishing a reference epigenome in arabidopsis seedlings GSE24651: h3k27me3-Establishing a reference epigenome in arabidopsis seedlings GSE24652: h3k27me2-Establishing a reference epigenome in arabidopsis seedlings GSE24653: h3k56ac-Establishing a reference epigenome in arabidopsis seedlings GSE24654: h4k20me1-Establishing a reference epigenome in arabidopsis seedlings GSE24655: h3-Establishing a reference epigenome in arabidopsis seedlings GSE24656: h2bub-Establishing a reference epigenome in arabidopsis seedlings GSE24657: h3k27me3_gw-Establishing a reference epigenome in arabidopsis seedlings GSE24658: h3k4me3_gw-Establishing a reference epigenome in arabidopsis seedlings GSE24659: h3k4me2_gw-Establishing a reference epigenome in arabidopsis seedlings GSE24660: 5mc_gw-Establishing a reference epigenome in arabidopsis seedlings GSE24661: h3k36me3_gw-Establishing a reference epigenome in arabidopsis seedlings GSE24662: h3k27me1_gw-Establishing a reference epigenome in arabidopsis seedlings GSE24663: h3_gw-Establishing a reference epigenome in arabidopsis seedlings GSE24664: h3k27me3_roots_gw-Establishing a reference epigenome in arabidopsis seedlings GSE24665: h3k4me3_roots_gw-Establishing a reference epigenome in arabidopsis seedlings Refer to individual Series
2011-04-19 | E-GEOD-24710 | biostudies-arrayexpress
Project description:Tyrosine kinase inhibitors (TKIs) directed against BCR-ABL1, the product of the Philadelphia (Ph) chromosome, have revolutionized treatment of patients with chronic myeloid leukemia (CML). However, acquired resistance to TKIs is a significant clinical problem in CML, and TKI therapy is much less effective against Ph+ B-cell acute lymphoblastic leukemia (B-ALL). BCR-ABL1, via phosphorylated Tyr177, recruits the adapter GAB2 as part of a GRB2/GAB2 complex. We showed previously that GAB2 is essential for BCR-ABL1-evoked myeloid transformation in vitro. Using a genetic strategy and mouse models of CML and B-ALL, we show here that GAB2 is essential for myeloid and lymphoid leukemogenesis by BCR-ABL1. In the mouse model, recipients of BCR-ABL1-transduced Gab2-/- bone marrow failed to develop CML-like myeloproliferative neoplasia. Leukemogenesis was restored by expression of GAB2 but not by GAB2 mutants lacking binding sites for its effectors PI3K or SHP2. GAB2 deficiency also attenuated BCR-ABL1-induced B-ALL, but only the SHP2 binding site was required. The SHP2 and PI3K binding sites were differentially required for signaling downstream of GAB2. Hence, GAB2 transmits critical transforming signals from Tyr177 to PI3K and SHP2 for CML pathogenesis, whereas only the GAB2-SHP2 pathway is essential for lymphoid leukemogenesis. Given that GAB2 is dispensable for normal hematopoiesis, GAB2 and its effectors PI3K and SHP2 represent promising targets for therapy in Ph+ hematologic neoplasms. RNA-Seq expression profiling of 6 mouse bone marrow samples: 3 GAB2 WT (+/+) and 3 GAB2 NULL (-/-)
2016-01-17 | E-GEOD-75615 | biostudies-arrayexpress
Project description:Tyrosine kinase inhibitors (TKIs) directed against BCR-ABL1, the product of the Philadelphia (Ph) chromosome, have revolutionized treatment of patients with chronic myeloid leukemia (CML). However, acquired resistance to TKIs is a significant clinical problem in CML, and TKI therapy is much less effective against Ph+ B-cell acute lymphoblastic leukemia (B-ALL). BCR-ABL1, via phosphorylated Tyr177, recruits the adapter GAB2 as part of a GRB2/GAB2 complex. We showed previously that GAB2 is essential for BCR-ABL1-evoked myeloid transformation in vitro. Using a genetic strategy and mouse models of CML and B-ALL, we show here that GAB2 is essential for myeloid and lymphoid leukemogenesis by BCR-ABL1. In the mouse model, recipients of BCR-ABL1-transduced Gab2-/- bone marrow failed to develop CML-like myeloproliferative neoplasia. Leukemogenesis was restored by expression of GAB2 but not by GAB2 mutants lacking binding sites for its effectors PI3K or SHP2. GAB2 deficiency also attenuated BCR-ABL1-induced B-ALL, but only the SHP2 binding site was required. The SHP2 and PI3K binding sites were differentially required for signaling downstream of GAB2. Hence, GAB2 transmits critical transforming signals from Tyr177 to PI3K and SHP2 for CML pathogenesis, whereas only the GAB2-SHP2 pathway is essential for lymphoid leukemogenesis. Given that GAB2 is dispensable for normal hematopoiesis, GAB2 and its effectors PI3K and SHP2 represent promising targets for therapy in Ph+ hematologic neoplasms.
2016-01-17 | GSE75615 | GEO
Project description:Srsf2P95H/+ mutation exacerbates Asxl1Y588XTg-induced leukemogenesis
| PRJNA1002285 | ENA
Project description:TET2 deficiency promotes MDS-associated leukemogenesis
| PRJNA881723 | ENA
Project description:TET2 deficiency promotes MDS-associated leukemogenesis
| PRJNA881305 | ENA